The drugs listed below were acquired from Selleck chem: FGFR inhibitors PD166866 (specific to FGFR1), Alofanib (targeting FGFR2), H3B-6527 (inhibiting FGFR4), and AZD4547 (effective against FGFR1-3), pan-FGFR inhibitor TAS-120, JAK inhibitors Solcitinib (inhibiting JAK1) and AZD1480 (inhibiting JAK2), UC2288 (p21 inhibitor), STAT inhibitors Fludarabine (inhibiting STAT1),
Stattic (inhibiting STAT3) and BAY2353 (Niclosamide, inhibiting STAT3), SGC-CBP30 (potent CREBBP/EP300 inhibitor), and ulixertinib (ERK1/ERK2 inhibitor). Human EGF protein and FGF ligands including FGF1, FGF2, FGF4, FGF7, FGF9, FGF8a, FG19 and FGF21 were purchased from PeproTech. The breast cancer cell lines CAMA1, MDA-MB-134, MCF7, and T47D were obtained from the American Type Culture Collection (ATCC). The CAMA1 and MCF7 cell lines were grown in DMEM with a 10% FBS and 1% antibiotic-antimycotic solution, while T47D and MDA-MB-134 were cultured in RPMI with 10% FBS and 1% antibiotic-antimycotic solution. Regular testing for mycoplasma contamination was conducted using the commercially available Myco Alert kit from Lonza. All cell lines utilized in this research have undergone authentication by ATCC, and only cells with a low number of passages were employed in experiments to ensure work confidence.
Stattic (inhibiting STAT3) and BAY2353 (Niclosamide, inhibiting STAT3), SGC-CBP30 (potent CREBBP/EP300 inhibitor), and ulixertinib (ERK1/ERK2 inhibitor). Human EGF protein and FGF ligands including FGF1, FGF2, FGF4, FGF7, FGF9, FGF8a, FG19 and FGF21 were purchased from PeproTech. The breast cancer cell lines CAMA1, MDA-MB-134, MCF7, and T47D were obtained from the American Type Culture Collection (ATCC). The CAMA1 and MCF7 cell lines were grown in DMEM with a 10% FBS and 1% antibiotic-antimycotic solution, while T47D and MDA-MB-134 were cultured in RPMI with 10% FBS and 1% antibiotic-antimycotic solution. Regular testing for mycoplasma contamination was conducted using the commercially available Myco Alert kit from Lonza. All cell lines utilized in this research have undergone authentication by ATCC, and only cells with a low number of passages were employed in experiments to ensure work confidence.